



5 February 2020

ZELIRA THERAPEUTICS SUCCESSFULLY COMPLETES CAPITAL RAISING OF A\$4,588,500

Highlights

- **Zelira Therapeutics has received commitments to raise circa A\$4,588,500 via a Placement to sophisticated investors**
- **The Placement was fully subscribed with strong support from existing and new shareholders**
- **The funds will be used to accelerate Zelira's plans to launch multiple products in global markets and to progress its clinical programmes**
- **The Company is now well funded to see it achieve significant value-add milestones and leverage its early mover advantage in launching clinically validated medicinal cannabis products**

The Board of **Zelira Therapeutics Ltd (ASX:ZLD, OTCQB: ZLDAF)** is pleased to announce it has successfully completed a placement of 91,770,000 fully-paid ordinary shares at a share price of A\$0.05 to Australian and International investors. The Placement will raise A\$4,588,500 before costs ("Placement").

Zelira's Managing Director (ex-USA), Dr Richard Hopkins, said, "The Placement was strongly supported by existing and new investors both domestically and in the United States. We are delighted to welcome new shareholders to our register and appreciate the ongoing support from our existing shareholders."

The Placement will increase the Company's cash position to approximately \$5,788,500 million before costs. The funds will be used to accelerate Zelira's plans to launch multiple products into global markets in 2020 and to advance its clinical programmes, including its Insomnia and Opioid Sparing trials, which are due to read-out in the first half of this year.

Subject to shareholder approval, Director Dr Richard Hopkins has committed to subscribe for approximately \$50,000 in the Placement.

Settlement is expected to occur on 10 February with the shares to be issued shortly thereafter. The Placement shares will be issued under the Company's existing 15% placement capacity under ASX Listing Rule 7.1, and accordingly will not require shareholder approval.

CPS Capital Group Pty Ltd (**CPS**) was mandated as Lead Manager to the Placement. The Placement was conducted under normal commercial terms with a fee of 6% paid to CPS.

The Company notes that Zelira Director Mr Peterson is a director and shareholder of CPS Capital Pty Ltd and may benefit from the fees received by CPS. The Board (excluding Mr Peterson) are satisfied that the fees payable to CPS are not inconsistent with fees charged for these services by other similar service providers.

This announcement has been authorised by the Managing Director of the Company.

Tim Slate

Company Secretary

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking:

- **Human clinical trial programs** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- **Pre-clinical research** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The Company conducts this work in partnership with world-leading researchers and organizations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA Pharm's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialization for successful clinically validated formulations.

The Company has developed two proprietary formulations (HOPE®) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products..

###

Address

Level 26
140 St Georges Terrace, Perth WA
6000 AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Australia Contact

Dr Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

U.S. Contacts:

Dr. Oludare Odumosu
Managing Director & CEO, USA
+1-909-855-0675
oodumosu@zeliratx.com
3553 West Chester Pike #110,
Newtown Square, PA 19073

GVM Communications, Inc.
Gia Morón,
347-678-8079 |
gia@gvmcommsinc.com

Tickers

Australia (ASX): ZLD USA
(OTCQB): ZLDAF